{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"179","value":"327"},{"groupId":"OG001","spread":"165","value":"403"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Cmax for lenvatinib was defined as the maximum observed concentration of lenvatinib in plasma following administration of study treatment on Cycle 1 Day 15 and was obtained directly from the measured plasma concentration-time curves.","dispersionType":"Standard Deviation","groups":[{"description":"Oral lenvatinib (18mg) and everolimus (5 mg) were taken once daily in the morning (consistently with or without food) with water, in continuous 28-day (4-week) cycles. Treatment cycles began with the first dose of study drug in Cycle 1 and continued in 28-day (4-week) consecutive cycles until completion of the off-treatment assessments (within 30 days after the last study treatment administration). Study drugs were administered at the clinic for the first dose and on the pharmacokinetic (PK) sampling days.","id":"OG000","title":"Phase 2: 18 mg Lenvatinib + 5 mg Everolimus"},{"description":"Oral lenvatinib (24 mg) was taken once daily in the morning (consistently with or without food) with water, in continuous 28-day (4-week) cycles.","id":"OG001","title":"Phase 2: 24 mg Lenvatinib"}],"paramType":"MEAN","populationDescription":"PK sub analysis set","reportingStatus":"POSTED","timeFrame":"Phase 2: Cycle 1 Day 15","title":"Maximum Concentration (Cmax) of Lenvatinib in Plasma When Administered Alone or in Combination With Everolimus","type":"SECONDARY","unitOfMeasure":"ng/mL"}